


Claims

- 1 A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:



wherein

X is N or CH;

R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro C₁₋₆alkyl, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -C(O)R⁷, -CO(CH₂)_nNR⁵R⁶, -SO₂R⁷, -SO₂NR⁵R⁶, -NR⁵SO₂R⁷, -NR⁵COR⁷ and -O(CH₂)_nCONR⁵R⁶;

R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, C₁₋₆alkyl or -NR⁵R⁶;

R⁵ and R⁶ are independently selected from hydrogen, C₁₋₆alkyl, perfluoroC₁₋₆alkyl, Het or C₁₋₄alkoxyC₁₋₄alkyl; or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, -CF₃, hydroxy, -OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy;

R⁷ is hydrogen or C₁₋₆alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C₁₋₆alkyl; and

n is 1-4.

- 2 A compound according to claim 1 wherein X is N.
- 3 A compound according to any preceding claim wherein R^1 is $-NR^5R^6$, $-(CH_2)_nNR^5R^6$, $-O(CH_2)_nNR^5R^6$, $-O(CH_2)_n-Het$, $-CONR^5R^6$, $-CO(CH_2)_nNR^5R^6$ or $-SO_2R^7$.
- 4 A compound according to any preceding claim wherein R^2 is hydrogen, C_{1-6} alkyl, chloro or fluoro.
- 5 A compound according to any preceding claim wherein R^3 is hydrogen or fluoro.
- 6 A compound according to any preceding claim wherein when X is N, R^2 is methyl.
- 7 A compound according to any preceding wherein when X is N and R^2 is methyl, R^3 is hydrogen.
- 8 A compound according to any preceding claim wherein R^4 is hydrogen, C_{1-6} alkyl or halo.
- 9 A compound according to any preceding claim wherein R^5 and R^6 are independently hydrogen, methyl or Het; or R^5 and R^6 together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7 membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl and C_{1-4} alkoxy.
- 10 A compound according to any preceding claim wherein R^5 and R^6 are independently hydrogen, methyl or tetrahydropyranyl; or R^5 and R^6 together with the nitrogen atom to which they are attached form a morpholine, pyrrolidine, piperazine ring, each of which may be substituted by halo (such

as fluoro, chloro, bromo), cyano, $-\text{CF}_3$, hydroxy, $-\text{OCF}_3$, C_{1-4} alkyl or C_{1-4} alkoxy.

11 A compound according to claim 1 wherein

X is N;

R^1 is $-\text{NR}^5\text{R}^6$, $-(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{O}(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{O}(\text{CH}_2)_n\text{-Het}$, $-\text{CONR}^5\text{R}^6$, $-\text{CO}(\text{CH}_2)_n\text{NR}^5\text{R}^6$ or $-\text{SO}_2\text{R}^7$;

R^2 is hydrogen, C_{1-6} alkyl, chloro or fluoro;

R^3 is hydrogen or fluoro;

R^4 is hydrogen, C_{1-6} alkyl or halo;

R^5 and R^6 are independently hydrogen, methyl or Het; or R^5 and R^6 together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7 membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-\text{CF}_3$, hydroxy, $-\text{OCF}_3$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^7 is hydrogen or C_{1-6} alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C_{1-6} alkyl; and

n is 1-4.

12 A compound according to claim 1 selected from the list:

3-[2-(4-methanesulfonyl-phenyl)-pyridin-4-yl]-2-(6-methyl-pyridin-2-yl)-imidazo[1,2-a]pyridine (Example 6);

3-[2-(4-(morpholin-4-yl)-phenyl)-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-a]pyridine (Example 14);

3-{2-[4-(4-methylpiperazin-1-yl)-phenyl]-pyridin-4-yl}-2-pyridin-2-yl-imidazo[1,2-a]pyridine (Example 15);

2-(6-methyl-pyridin-2-yl)-3-[2-(4-(morpholin-4-ylmethyl)phenyl)-pyridin-4-yl]-imidazo[1,2-a]pyridine (Example 16);

2-(6-methyl-pyridin-2-yl)-3-{2-[4-((morpholin-4-yl)carbonyl)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 29);

2-(pyridin-2-yl)-3-{2-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 34);
7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 38);
7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-((1-methyl-imidazol-4-yl)methoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 41); and
7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4(aminocarbonylmethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 43);
and pharmaceutically acceptable salts, solvates and derivatives thereof.

- 13 A pharmaceutical composition comprising a compound defined in any preceding claim and a pharmaceutically acceptable carrier or diluent.
- 14 The use of a compound defined in any one of claims 1 to 12 in the manufacture of a medicament for the treatment or prophylaxis of a disorder mediated by the ALK5 receptor in mammals.
- 15 The use according to claim 14 wherein the disorder is selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV), hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis, mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis, endometriosis, keloids and restenosis.
- 16 The use according to claim 15 wherein the disorder is kidney fibrosis.
- 17 A compound defined in any one of claims 1 to 12 for use as a medicament.